Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].

Lheureux S, Joly F.

Bull Cancer. 2012 Sep;99(9):875-80. doi: 10.1684/bdc.2012.1617. French.

2.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
3.

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.

Paller CJ, Antonarakis ES.

Drug Des Devel Ther. 2011 Mar 10;5:117-24. doi: 10.2147/DDDT.S13029. Review. Erratum in: Drug Des Devel Ther. 2011;5:183.

4.

Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.

Keating GM.

Drugs Aging. 2013 May;30(5):359-65. doi: 10.1007/s40266-013-0078-8. Review.

PMID:
23532557
5.

Cabazitaxel for the treatment of castration-resistant prostate cancer.

Agarwal N, Sonpavde G, Sartor O.

Future Oncol. 2011 Jan;7(1):15-24. doi: 10.2217/fon.10.168.

PMID:
21174534
6.

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.

Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J.

Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16. Review.

PMID:
23867574
7.

TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.

Oudard S.

Future Oncol. 2011 Apr;7(4):497-506. doi: 10.2217/fon.11.23.

PMID:
21463139
8.

Chemotherapy-based treatment for castration-resistant prostate cancer.

Seruga B, Tannock IF.

J Clin Oncol. 2011 Sep 20;29(27):3686-94. doi: 10.1200/JCO.2010.34.3996. Epub 2011 Aug 15. Review. Erratum in: J Clin Oncol. 2011 Dec 20;29(36):4847. Dosage error in article text.

PMID:
21844499
9.

Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.

Ansari J, Hussain SA, Alhasso A, Mahmood R, Ansari A, Glaholm J.

Anticancer Agents Med Chem. 2011 Mar;11(3):296-306. Review.

PMID:
21426298
10.

[Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].

Ecstein-Fraisse E, Su Z.

Gan To Kagaku Ryoho. 2014 Jul;41(7):817-22. Japanese.

PMID:
25131866
11.

Critical appraisal of cabazitaxel in the management of advanced prostate cancer.

Pal SK, Twardowski P, Sartor O.

Clin Interv Aging. 2010 Dec 3;5:395-402. doi: 10.2147/CIA.S14570. Review.

12.

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.

Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.

Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29.

13.

Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.

Parente P, Parnis F, Gurney H.

Asia Pac J Clin Oncol. 2012 Mar;8(1):31-42. doi: 10.1111/j.1743-7563.2011.01506.x. Review.

PMID:
22369442
14.

Practical guide to the use of chemotherapy in castration resistant prostate cancer.

Petrylak DP.

Can J Urol. 2014 Apr;21(2 Supp 1):77-83. Review.

15.

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.

Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Epub 2013 Aug 16. Review.

16.
17.

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S, Gong C, Malmstrom R, Wilson L.

PLoS One. 2013 May 22;8(5):e64275. doi: 10.1371/journal.pone.0064275. Print 2013.

18.

[New treatments for castration-resistant prostate cancer].

Sautois B, Gennigens C.

Rev Med Liege. 2013 Feb;68(2):94-6. French.

19.

[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].

Pouessel D, Oudard S, Gravis G, Priou F, Shen L, Culine S.

Bull Cancer. 2012 Jul-Aug;99(7-8):731-41. doi: 10.1684/bdc.2012.1608. French.

PMID:
22743148
20.

Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.

Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, Van Oort I, Papandreou C, Fossa S, Hitier S, Climent MA; European investigators.

Eur J Cancer. 2014 Apr;50(6):1090-9. doi: 10.1016/j.ejca.2014.01.006. Epub 2014 Jan 31.

Supplemental Content

Support Center